Barclays’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Barclays’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,778	Closed	-$110K	–	5393
2020 Q4	$110K	Sell	4,778 -26,847	-85%	-$340K	﹤0.01%	4096
2020 Q3	$322K	Buy	31,625 +14,493	+85%	+$194K	﹤0.01%	3538
2020 Q2	$255K	Buy	17,132 +7,216	+73%	+$111K	﹤0.01%	3875
2020 Q1	$121K	Buy	9,916 +2,352	+31%	+$37.4K	﹤0.01%	4668
2019 Q4	$119K	Buy	7,564 +3,761	+99%	+$48K	﹤0.01%	5378
2019 Q3	$47K	Buy	+3,803	New	+$43.1K	﹤0.01%	5943

Barclays's PRVL Position: Q1 2021 in Review

Barclays sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 4,778 shares — an estimated $110K sold.

Barclays first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $322K in Q3 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Barclays reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Barclays sold 4,778 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $110K.
Barclays first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
Barclays's Prevail Therapeutics Inc. Common Stock position peaked at $322K in Q3 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Barclays's 13F filing for Q1 2021, filed 13 May 2021.